Ondansetron Noridem (Ondansetron)

Ondansetron Noridem is a selective 5‑HT3 receptor antagonist used across several nausea‑vomiting pathways.

• Chemotherapy‑induced nausea and vomiting: helps to control the acute and delayed phases of CINV.
• Radiotherapy‑induced nausea and vomiting: reduces the frequency of nausea during and after radiation treatment.
• Post‑operative postoperative vomiting: less the incidence of vomiting after surgical procedures.
• Pregnancy‑related nausea: supports symptom relief in early pregnancy, though clinical use varies.
• Hyper‑emesis gravidarum (rarely used): may be considered when conventional therapy fails.

• Ondansetron blocks the serotonin 5‑HT3 receptors located on vagal afferent nerves in the gastrointestinal tract and in the chemoreceptor trigger zone of the brain. By preventing serotonin from binding to these receptors, it interrupts the neural signaling cascade that initiates the vomiting reflex, thereby reducing nausea and vomiting associated with chemotherapy, radiation and surgery.

Adverse reactions to ondansetron are generally mild but can vary in severity.

Common Side Effects

• Headache: mild to moderate intensity.
• Constipation: occasional bowel movement reduction.
• Diarrhoea: loose stools in a minority of patients.
• Fatigue: feeling of tiredness or reduced energy.
• Dizziness: transient light‑headed sensations.
• Injection site pain (if administered intravenously).

Serious or Rare Side Effects

• Cardiac arrhythmia: QT‑interval prolongation, especially with high IV doses.
• Severe allergic reaction: rash, itching, swelling, or anaphylaxis.
• Serotonin syndrome: rare when combined with other serotonergic agents.
• Hepatic enzyme elevation: abnormal liver function tests.
• Vision changes: blurred vision or visual disturbances.
• Severe hypotension: sudden drop in blood pressure after rapid IV administration.

When using Ondansetron Noridem, consider the following safety measures:

• Cardiac monitoring: patients with known QT prolongation or electrolyte imbalance should be observed.
• Concomitant serotonergic drugs: avoid combining with other agents that increase serotonin levels.
• Pregnancy: use only if the potential benefit outweighs risk; discuss with a healthcare professional.
• Breastfeeding: limited data; weigh benefits against possible infant exposure.
• Renal or hepatic impairment: dose adjustment may be required; monitor function.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ondansetron may interact with several drug classes, altering efficacy or safety.

Major Interactions (Avoid)

• Apomorphine: may cause profound hypotension and loss of consciousness.
• Certain anti‑arrhythmic agents (e.g., quinidine, amiodarone): increase risk of QT prolongation.
• Serotonergic agents (e.g., SSRIs, MAOIs, tramadol): elevate risk of serotonin syndrome.

Moderate Interactions (Monitor Closely)

• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise ondansetron plasma levels.
• CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): modestly increase exposure.
• Antacids containing aluminium or magnesium: can reduce oral absorption if taken simultaneously.